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92 Poster Session-IBronchoscopic BAL (B-BAL) is performed by physicians, using
video-bronchoscope. Non-bronchoscopic BAL (NB-BAL) is per-
formed by respiratory therapists (RT), without direct visualization
of the lower airways. Generally, B-BAL is considered more effective
thanNB-BALdue to concern thatNB-BALperformed byRT can be
associated with higher incidence of complications, especially bleed-
ing. We compared the two methods for obtaining BAL and studied
themicrobiological yield, safety and cost-effectiveness of B-BAL and
NB-BAL in critically ill cancer patients.
Method: Following IRB approval, medical records of all intu-
bated and mechanically ventilated adult ICU patients with pulmo-
nary infiltrates, who underwent either B-BAL or NB-BAL between
8/1/2006 and 10/31/2006, were retrospectively studied. B-BAL
was performed by intensivist or pulmonologist and NB-BAL was
performed using 16Fr Kimberly Clark’s protected BAL catheter,
by experienced and skilled RT according to specific department pol-
icy. The BAL samples were taken from the lower lobe bronchial seg-
ments.Table 1. A comparison of B-BAL and NB-BAL in patients with
hematological malignancies.
Patient Charecteristics n B-BAL NB-BAL44 22 22
Age yrs
Median 52 49 55
Range 20-79 20-79 28-72
M/F 29/15 15/7 14/8Diagnosis
Leukemia 16 10 6
Lymphoma 13 5 8
SCT recipients 13 7 6
Myeloma 1 0 1
Hypereosinophilic syndrome 1 0 1WBC count K/UL
Median 3.3 0.3 5.0
Range 0.1-102 0.1-18 0.1-102Platelet count K/UL
Median 42 29 59
Range 5-321 5-247 23-321
Complications 0 0 0
Microbiological yield 20/44 (46%) 11/22 (50%) 9/22 (41%)Cost per procedure $ 2427 125
SCT recipients
Platelet count K/UL
Median 51 27 52
Range 19-247 19-247 24-98WBC count K/UL
Median 5.2 6.6 3.25Range 0.1-21.2 3.3-9.0 0.1-21.2
Microbiological yield 7/13 (54%) 4/7 (57%) 3/6 (50%)Results:During the study period, 44 critically ill patients with he-
matological malignancies including 13 SCT recipients underwent
BAL. Four patients had received SCT within the prior 4 weeks of
BAL. An equal number of NB-BAL and B-BAL was performed. Pa-
tient characteristics,WBC counts, platelet counts, procedure related
complications, microbiological yield and cost per procedure associ-
ated with B-BAL and NB-BAL are shown in table 1. The most fre-
quently identified organisms were Pseudomonas aeruginosa,
Coagulase negative staphylococcus, Stenotrophomonas maltophilia,
and Candida spp.
Conclusion: Both B-BAL and NB-BAL can be safely performed
in patients with hematological malignancies including SCT recipi-
ents. Microbiological yield is similar between physician performed
B-BAL and RTperformedNB-BAL in critically ill patients with pul-
monary infiltrates. However, the cost of B-BAL is 20 times higher
thanNB-BAL for similar yield, due to physician resource utilization.
Hence, NB-BAL should be considered as a safe alternative whenever
feasible.253
CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF DISSEMI-
NATED TRICHOSPORONOSIS: SURVEY OF 67 PATIENTS WITH HEMATO-
LOGICAL DISEASE
Fukuda, T.1, Sugita, T.2, Takakura, S.3, Takata, T.4, Kushima, H.5,
Takaue, Y.1, Tamura, K.4, Tokimatsu, I.5 1National Cancer Center Hos-
pital, Tokyo, Japan; 2Meiji Pharmaceutical University; 3Kyoto University
Hospital; 4Fukuoka University; 5Oita University
Background: Disseminated infection by Trichosporon species
(DT) is an uncommon but frequently fatal mycosis in neutropenic
patients, including recipients of hematopoietic stem cell transplanta-
tion (HSCT). However, little is known about the clinical character-
istics and treatment outcome of DT due to its rarity.
Methods: A questionnaire was sent to 468 hospitals in Japan to
survey DT, which was defined as infectious symptoms associated
with positive blood culture for Trichosporon species. In selected pa-
tients, genetic subtypes and antifungal susceptibility of the isolates
were analyzed.
Results: Between 2000 and 2007, 67 patients (median age, 57
years: range, 16–78) with a variety of hematological diseases devel-
oped DT. The diagnosis included acute myeloid leukemia (n 5
39), acute lymphoblastic leukemia (8), chronic myeloid leukemia
(6), and lymphoma (6), and 28 patients (42%) were recipients of
HSCT. At the onset of DT, 55 patients (82%) had an absolute neu-
trophil count below 500 /mm3, and 58 patients (87%) had been re-
ceiving antifungal agents, including micafungin (MCFG) in 39
patients. In 35 patients (52%), Trichosporon species were detected
in various organs including lung (n 5 18), kidney (12), heart (6),
and skin (6). A beta-D-glucan test was positive in 43 of the 62 eval-
uated patients (median, 96 pg/ml; range, 22–3961). Whereas 2 iso-
lates of T. asahi appeared to be resistant to all antifungal agents
including azoles, 22 isolates showed good susceptibility to voricona-
zole, but not to MCFG. Although 56 of the 67 patients (84%) re-
ceived various antifungal agents for DT, the mortality rate within
30 days was 67% (median survival time, 13 days). Overall survival
was significantly better in patients who received azoles rather than
amphotericin products without azole (p5 0.0002). In a multivariate
analysis, treatment without azoles for DT and recipients of HSCT
were associated with a higher probability of day-30 mortality after
the development of DT.
Conclusions:Our study suggests that most cases of DT occurred
as a breakthrough infection, especially in patients who had received
MCFG. Although mortality after the development of DT was high,
it is possible that prompt initiation of treatment with azoles may
improve survival.254
IMPACT OF PRE-STEM CELL TRANSPLANT FERRITIN LEVELS ON LATE
TRANSPLANT COMPLICATIONS. A LANDMARK ANALYSIS TO DETERMINE
POTENTIAL ROLE OF IRON CHELATION IN IMPROVING TRANSPLANT
OUTCOMES
Efebera, Y.1, Saliba, R.M.1, Thandi, R.S.1, Popat, U.1, De Lima, M.1,
Alousi, A.1, Hosing, C.1, Ledford, M.2, Champlin, R.1, Giralt, S.1 1Uni-
versity of Texas M.D. Anderson Cancer Center, Houston, TX; 2Novartis
Pharmaceuticals, East Hanover, NJ
Background: Iron overload has been associated with increased
treatment-related mortality (TRM) in patients with AML/MDS un-
dergoing hematopoietic stem cell transplantation (HSCT). Defara-
sinox (D) is an orally-active iron chelator that at doses of 20 and
30 mg/kg maintain or reduce liver iron concentration in transfusion
dependent patients with MDS or hemoglobinopathies. The most
common adverse events associated with D are skin rash (26%), ab-
dominal pain (21%), and creatinine elevation (20%). These adverse
effect overlap with commonly acute side effects seen after allograft-
ing and together with the creatinine elevations make exploring the
role of D early after HSCT (ie first 90 days) difficult. Notwithstand-
ing, a significant proportion of non-relapse deaths still occur be-
tween 3 and 12 months post HSCT. Since high ferritin (F) levels
pre HSCT have been associated with increases in NRM rates post
HSCT we hypothesized that this relationship would persist even
in patients surviving more than 3 months post SCT, which would
suggest a potential role for iron chelation in patients surviving at least
3 months post HSCT.
Poster Session-I 93Patient and Methods: Retrospective analysis of transplant out-
comes in patients with AML/MDS patients who underwent an allo-
geneic transplant with peripheral blood or bone marrow from
a sibling or unrelated donor transplant during the year 2006 at
MDACC, had a pre-SCT F level determined and were alive and dis-
ease free at 90 days post HSCT.
Results: A total of 106 patients with AML/MDS underwent allo-
geneic transplant during that time period of which 90 patients were
alive without relapse by day 90 and complete data including pre
HSCT F levels were available for 77 patients. Patient characteristics
and relationship of pre SCT F on transplant outcomes in patients
surviving at least 90 days is summarized in Table 1. Patients with
the lowest pre SCT-F levels (ie Q1) had the best outcomes when
compared to patients with higher levels (Q2-Q4) . There was a trend
towards improved survival in patients with the lowest level of F pre
SCT when compared to the other patients (p 5 0.09). All patients
had a significant increase in their F levels by D90 post SCT when
compared to Pre SCT.
Conclusions: Pre SCT F levels may still have an impact in SCT
events that happen 3 months after transplant. This together with
continuous rise in F levels post SCT support further studies of
iron chelation therapy post SCT.
Results
1st Quartile F 2nd-4th Quartile F
(\1027 ng/dl) (1028-6714 ng/dl) p valueN 20 57
Median Age (range) 49 (22-70) 53 (21-68) 0.7
%PBSC 90 63 0.02
%Sib Donor 61 33 0.04
%RIC 45 53 0.6
% Remission @ SCT 55 44 0.4
OS @ 1 year 85% 62% 0.09
CGVHD @ 18m 46% 32% 0.08
%NRM @ 1 year 10 18 0.4
F level @ 3 months 1648 (108-5316) 2971 (1134-15437) 0.02255
TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN ADULT
PATIENTS WITH HEMATOLOGIC MALIGNANCIES ON AN INSTITUTION-
SPECIFIC GUIDELINE
Wong, E., Kuyumjian, A.G., Wynd, M.A., Surowiec, D., DeSevo, G.M.,
Patel, A.A., Munk, G., Sebti, R. Hackensack University Medical Center,
Hackensack, NJ
Background: Respiratory syncytial virus (RSV) infections are
associated with increased mortality in patients with hematologic
malignancies. A guideline was developed by the Antimicrobial Stew-
ardship Program with an interdisciplinary approach to facilitate the
treatment of RSV-infections. The objective of this study is to
describe the outcome of RSV-infected adult patients with hemato-
logic malignancies since the implementation of this guideline.
Methods: A retrospective chart review was conducted on RSV-
infected patients$18 years old and treated with aerosolized ribavirin
6 intravenous palivizumab during the period of September 2006
through May 2008. Infections were confirmed by rapid antigen
detection immunoassay and tissue culture inoculation of nasopha-
ryngeal swab specimens. Data collection included: patient demo-
graphics, clinical presentation, diagnostic studies, time-elapsed
post-hematopoietic stem cell transplant (if applicable), treatment
administered, and 30 and 90 day mortality.
Results: Of the 26 patients identified, 13 had upper respiratory
tract infection only and 13 had upper and lower respiratory tract
infection. The mean age (6 SD) was 51.5 6 11 years. Twenty-one
patients were hematopoietic stem cell transplant recipients (13 allo-
geneic, 8 autologous). All patients received aerosolized ribavirin.
Thirteen patients received aerosolized ribavirin plus intravenous
palivizumab. The treatment of 20 patients was consistent with the
institution’s guideline. Within 30 and 90 days of RSV diagnosis,
the mortality was 0 and 2 patients, respectively. Neither death was
attributed to RSV.Conclusion: An institution-specific treatment guideline offers
a systematic approach to the management of RSV-infected adult
patients and may improve RSV-related outcomes.256
EFFECT OF RED BLOOD CELL STORAGE AGE ON OUTCOMES IN NON-
HODGKIN LYMPHOMA PATIENTS RECEIVING AUTOLOGOUS STEM CELL
TRANSPLANTATION
Ramaekers, R.C., Loberiza, F.R., Bierman, P.J., Landmark, J.D. Uni-
versity of Nebraska Medical Center, Omaha, NE
Conflicting literature exists on whether the storage age of red
blood cells (RBC) prior to transfusion affects patient outcomes. In
the setting of cardiac surgery, it was found that RBC’s stored longer
than 15 days prior to transfusion resulted in inferior outcomes. We
evaluated the influence of RBC storage age on patient outcomes after
autologous stem cell transplantation (ASCT).We conducted a retro-
spective cohort study of 361 consecutive patients requiring RBC
support after undergoing first ASCT for non-Hodgkin lymphoma
(NHL) between 2000 and 2006 at the University of Nebraska
Medical Center. Consistent with other studies, the main variable
we evaluated was the maximum age of transfused RBC’s, dichoto-
mized according to median storage age. Patient-, disease-, and treat-
ment-related variables were compared according to median
maximum age of RBC transfused (#34 vs..34 days) usingWilcoxon
and Chi-square tests. Cox proportional hazards regression analysis
was used to assess whether storage duration of RBC’s was associated
with transplant outcome. A total of 191 (53%) and 170 (47%)
patients received RBC transfusion from blood with maximum stor-
age age of #34 days (younger) and .34 days (older), respectively.
Patients receiving older RBC transfusion were likely to be older,
had a longer interval from NHL diagnosis to transplantation, had
more advanced disease at NHL diagnosis, and were more likely to
be in relapse at the time of transplantation. Patients in the younger
RBC’s group were transfused fewer units (median 3 vs. 5; P 5
\0.001) and had a significantly lower median age of all units trans-
fused (21 vs. 32 days; P 5 \0.001). There were no differences
between the younger and older transfused groups in terms of median
length of hospital stay (12 vs. 13 days; P 5 0.13), 100-day survival
rate (94% vs. 94%; P 5 0.96), or 1-year overall survival (85% vs.
85%; P 5 0.90). After adjusting for significant prognostic variables
in the multivariate analysis, the risk of death for patients transfused
with older blood was not significantly different from those receiving
younger RBC’s (Hazard Ratio 0.96; 95%CI 0.65–1.42, P5 0.85). In
conclusion, our single-institution cohort analysis of NHL patients
undergoing ASCT failed to demonstrate any significant differences
in outcomes according to the storage age of transfused RBC’s.257
VALUE OF SURVEILLANCE CULTURE IN PREDICTING CAUSATIVE PATHO-
GENS OF SEPTICEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tanaka, Y.1, Kiuchi, K.1, Kudo, M.1, Kurotori, T.1, Yamamoto, S.1,
Tsujimura, N.1, Yamada, K.1, Yashima, T.1, Mori, T.2, Okamoto, S.2
1Keio University Hospital, Tokyo, Japan; 2Keio University School of Med-
icine, Tokyo, Japan
Background: Recipients of allogeneic hematopoietic stem cell
transplantation (HSCT) are susceptible to fatal bacterial infection
because of long-term severe neutropenia and mucositis. Initiating
an appropriate antimicrobial therapy immediately on developing
bacterial infection is essential for improving survival. Surveillance
culture can be used as a useful additional measure in themanagement
of infection by predicting the causative pathogen. In the present
study, we have evaluated the value of surveillance culture in septice-
mia diagnosed after allogeneic HSCT.
Patients and Methods: Among 116 recipients of allogeneic
HSCT performed for hematological diseases at Keio University
Hospital, 40 episodes of septicemia were observed. All patients had
received ciprofloxacin (600 mg/day) and fluconazole (200 mg/day)
orally for the prophylaxis of bacterial and fungal infection starting
14 days before HSCT. Surveillance culture was performed by
obtaining samples from the throat and feces once weekly, starting
